All In Biotech

Free tool

FAERS Monitor: Fabior

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202428 or its brand name (Fabior, Tazarotene). Reports on generic versions are filed under their own applications.

Reports

466

Serious

130

28% of reports

Hospitalization

53

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective60
  • erythema42
  • skin exfoliation41
  • off label use39
  • application site erythema31
  • rash31
  • pruritus29
  • application site pain27
  • pain23
  • product use in unapproved indication18
  • application site discolouration17
  • burning sensation17
  • nausea17
  • skin irritation17
  • application site exfoliation16

Reports by year received

View as table
YearReports
20042
20061
20073
20083
20092
20103
20114
20122
20135
201437
201515
201619
20177
201846
201945
202031
202125
202240
202375
202435
202528
202638

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,693 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site discolourationSignal17189.6118.82,992
application site exfoliationSignal16176.0108.62,602
application site painSignal2755.438.41,388
application site erythemaSignal3153.438.01,544
skin exfoliationSignal4121.916.4802
skin irritationSignal1716.810.5237
burning sensationSignal1710.96.9144
erythemaSignal429.26.9303
pruritusSignal293.42.448
product use in unapproved indicationSignal183.32.127
rashSignal313.22.346
drug ineffectiveSignal602.11.634
off label useSignal392.01.520
pain231.71.16
nausea171.00.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.